Author | Rory Cochran, BS


TORn in Two Over Breast Cancer Drug Resistance

January 15, 2013

ByRory Cochran, BS|Josh Lauring, MD, PhD|Ben Ho Park, MD, PhD

Knowing the genetic makeup of patient tumors permits the development of new DNA-based diagnostics, such as BEAMing and PARE. By incorporating these new tools into future trials, we should be able to concurrently learn about drug resistance and significantly improve patient responses.